Probiotic and Peanut Oral Immunotherapy Studies (PPOIT)

The prevalence of food allergy has increased, particularly in westernised countries. The need for a curative treatment is greatest for peanut allergy because this is usually life-long and the most common cause of anaphylaxis-related fatality. Oral immunotherapy (OIT) has been explored as a strategy to induce tolerance to food allergens.

The PPOIT (probiotic and peanut oral immunotherapy) trials are a series of studies investigating the use of the probiotic Lactobacillus rhamnosus and peanut OIT to induce sustained unresponsiveness to peanut, in other words, a possible effective treatment for peanut allergy. The inclusion of a probiotic has been postulated to enhance the tolerogenic effect of OIT.

Study Summary
Study name Probiotic and Peanut Oral Immunotherapy Studies
Study abbreviation PPOIT
Current principal investigator/s Mimi Tang
Current project manager

Melanie Lloyd

 

Primary Institution/s The Royal Children’s Hospital - RCH
Murdoch Children’s Research Institute - MCRI
Major funding source/s National Health and Medical Research Council - NHMRC
Murdoch Children’s Research Institute - MCRI
Food Allergy and Anaphylaxis Network - FAAN
Study website https://www.foodallergyresearch.org.au/researchers/food-allergy-studies/ppoit-003/
Key reference for study Tang, M.L., Ponsonby, A.-L., Orsini, F., Tey, D., Robinson, M., Su, E.L., Licciardi, P., Burks, W. and Donath, S. (2015). Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol. 135(3): 737-44.e8. doi: 10.1016/j.jaci.2014.11.034
Study focus

The PPOIT (probiotic and peanut oral immunotherapy) trials are a series of studies investigating the use of the probiotic Lactobacillus rhamnosus and peanut OIT to induce sustained unresponsiveness to peanut, in other words, a possible effective treatment for peanut allergy.

Sampling frame

Children with clinically proven peanut allergy were recruited through the Royal Children’s Hospital (Melbourne) Department of Allergy/Murdoch Children's Research Institute (RCH/MCRI), also through Immunology outpatient clinics and the general community through media. For PPOIT-3, participants were also recruited from the Women’s and Children’s Hospital Adelaide and Perth Children’s Hospital / Princess Margaret Hospital.

Primary study type Randomised Control Trial / Other trial
Year commenced

2008

Is this study ongoing? Yes - we plan to continue the study (subject to future funding)
Ongoing recruitment? No
Sample size (N)

PPOIT-1: 62; PPOIT-2: 20; PPOIT-3: 201.

Survey data available? Yes
Imaging data available? No
Linkage to administrative dataset/s? Yes, linkage to (at least one) administrative dataset underway
Biosamples available? Yes
Are data available to others outside study team, with appropriate safeguards and structures in line with the cohort’s ethics and governance processes? No
Are there any costs associated with data/sample access for approved requests? There may be costs associated with access, evaluated on a case by case basis
Broadest type of participant consent available Specific consent (can be used for this project only)
Study Contacts
Principal investigator/s Mimi Tang
Project manager

Melanie Lloyd

 

Study Contact

Email: peanut.study@mcri.edu.au
Address: Allergy and Immune Disorders
Murdoch Children’s Research Institute
Flemington Rd
Parkville, Victoria 3052
Australia